Cytokine Signalling Forum
CME Courses
Cytokine Signalling Inhibitors: Update from EULAR 2020
Release date: 29 July 2020 Cytokine Signalling Inhibitors: Update from EULAR 2020Developed by CESAS Medical, under the auspices of the University of Glasgow. This activity is supported by unrestricted educational grants from Lilly, AbbVie, Gilead/Galapagos and Pfizer
Estimated time to complete activity: 1 hour
Compatible with all modern internet browsers and mobile devices
EDUCATIONAL OBJECTIVES
After completing this activity, the learner will:
- Understand the mode of action of JAK inhibitors
- Be up to date on the safety and efficacy of JAK Inhibitors in RA, JIA and PsA
- Understand the clinical predictors and comparative effectiveness of JAK inhibitors in patients with RA
TARGET AUDIENCE
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.
PROGRAMME OVERVIEW
EULAR 2020 presented new scientific and clinical information on cytokine signalling science that will shape the rheumatology treatment landscape. Data presented included those relating to JAK inhibitors in clinical practice and in development across RA, JIA and PsA.
In this activity, Cytokine Signalling Inhibitors: Update from EULAR 2020, international experts review and discuss key abstracts and data from EULAR 2020 specifically relating to the mode of action, safety and efficacy, and comparative effectiveness of JAK inhibitors.
This course, Cytokine Signalling Inhibitors: Update from EULAR 2020, outlines recent developments in cytokine signalling science in RA, JIA and PsA, and discusses the importance of these new data for clinical practice. The learner’s understanding of the information presented will be assessed following each of the course modules.
INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.
DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.
ACCREDITATION STATEMENT
The e-learning activity, Cytokine Signalling Inhibitors: Update from EULAR 2020, organised by CESAS Medical, under the auspices of the University of Glasgow, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The e-learning activity, Cytokine Signalling Inhibitors: Update from EULAR 2020, organised by CESAS Medical, under the auspices of the University of Glasgow, is awarded 1 European CME credits (ECMECs).
Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
| Module | Presenter | Video | Questions |
|---|---|---|---|
| Introduction |
Professor Rieke Alten
Head of Department of Internal Medicine, Rheumatology, Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
|
02:30 | |
| Module 1 - Basic Science |
Professor Rieke Alten
Head of Department of Internal Medicine, Rheumatology, Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Professor Thomas Dörner
Professor and Principal Investigator , Professor Thomas Dörner is a Professor of Rheumatology at Charité University Hospitals, Berlin, and group leader at the German Research Centre of Rheumatology, Berlin (DRFZ).
He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995. He undertook a postdoctoral fellowship at the University of Texas, Southwestern Medical Centre at Dallas, where he researched delineating molecular aspects of the B-cell receptor gene usage in autoimmune diseases.
Professor Dörner has led various clinical trials of rheumatic diseases, including systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue. He also explores innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.
Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases. He has received a number of awards including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.
|
05:37 | 3 |
| Module 2 - Safety and Efficacy |
Professor Rieke Alten
Head of Department of Internal Medicine, Rheumatology, Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Professor Thomas Dörner
Professor and Principal Investigator , Professor Thomas Dörner is a Professor of Rheumatology at Charité University Hospitals, Berlin, and group leader at the German Research Centre of Rheumatology, Berlin (DRFZ).
He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995. He undertook a postdoctoral fellowship at the University of Texas, Southwestern Medical Centre at Dallas, where he researched delineating molecular aspects of the B-cell receptor gene usage in autoimmune diseases.
Professor Dörner has led various clinical trials of rheumatic diseases, including systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue. He also explores innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.
Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases. He has received a number of awards including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.
|
35:23 | 4 |
| Module 3 - Predictors of Effectiveness and Comparative Effectiveness |
Professor Rieke Alten
Head of Department of Internal Medicine, Rheumatology, Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Professor Thomas Dörner
Professor and Principal Investigator , Professor Thomas Dörner is a Professor of Rheumatology at Charité University Hospitals, Berlin, and group leader at the German Research Centre of Rheumatology, Berlin (DRFZ).
He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995. He undertook a postdoctoral fellowship at the University of Texas, Southwestern Medical Centre at Dallas, where he researched delineating molecular aspects of the B-cell receptor gene usage in autoimmune diseases.
Professor Dörner has led various clinical trials of rheumatic diseases, including systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue. He also explores innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.
Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases. He has received a number of awards including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.
|
06:30 | 3 |
| Close |
Professor Rieke Alten
Head of Department of Internal Medicine, Rheumatology, Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
|
01:21 | |
| Evaluation | 16 |
Date of preparation: 27 July 20